Review



simplechiptm human id1 promoter primers  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc simplechiptm human id1 promoter primers
    Effect of cyclin D1 and <t>Id1</t> on breast cancer cell protein expression and migration . Actively cycling MDA-MB-231 and ZR75-1 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in gene or protein expression, and migration. Blots are representative, and plots are mean values from at least three independent experiments. Error bars represent standard deviation. MDA-MB-231 cells: (A) Microarray analysis. Left panel: CCND1 gene expression, right panel: ID1 gene expression (B) Western blot for cyclin d1, Id1 and Actin protein, (C) Cell migration as measured by Boyden chamber assay, dots indicate total number of migrated cells. (D) ChIP assay for Id1 promoter region following cyclin D1 pull down. ZR75-1: (E) Western blot for cyclin d1 and Actin protein (F) Cell migration- Boyden chamber assay. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.
    Simplechiptm Human Id1 Promoter Primers, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/simplechiptm+human+id1+promoter+primers/SimpleChIP+Human+ID1+Promoter+Primers/pmc03192789-81-22-27
    Average 93 stars, based on 1 article reviews
    simplechiptm human id1 promoter primers - by Bioz Stars, 2026-10
    93/100 stars

    Images

    1) Product Images from "Cyclin D1, Id1 and EMT in breast cancer"

    Article Title: Cyclin D1, Id1 and EMT in breast cancer

    Journal: BMC Cancer

    doi: 10.1186/1471-2407-11-417

    Effect of cyclin D1 and Id1 on breast cancer cell protein expression and migration . Actively cycling MDA-MB-231 and ZR75-1 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in gene or protein expression, and migration. Blots are representative, and plots are mean values from at least three independent experiments. Error bars represent standard deviation. MDA-MB-231 cells: (A) Microarray analysis. Left panel: CCND1 gene expression, right panel: ID1 gene expression (B) Western blot for cyclin d1, Id1 and Actin protein, (C) Cell migration as measured by Boyden chamber assay, dots indicate total number of migrated cells. (D) ChIP assay for Id1 promoter region following cyclin D1 pull down. ZR75-1: (E) Western blot for cyclin d1 and Actin protein (F) Cell migration- Boyden chamber assay. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.
    Figure Legend Snippet: Effect of cyclin D1 and Id1 on breast cancer cell protein expression and migration . Actively cycling MDA-MB-231 and ZR75-1 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in gene or protein expression, and migration. Blots are representative, and plots are mean values from at least three independent experiments. Error bars represent standard deviation. MDA-MB-231 cells: (A) Microarray analysis. Left panel: CCND1 gene expression, right panel: ID1 gene expression (B) Western blot for cyclin d1, Id1 and Actin protein, (C) Cell migration as measured by Boyden chamber assay, dots indicate total number of migrated cells. (D) ChIP assay for Id1 promoter region following cyclin D1 pull down. ZR75-1: (E) Western blot for cyclin d1 and Actin protein (F) Cell migration- Boyden chamber assay. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

    Techniques Used: Expressing, Migration, Transfection, Plasmid Preparation, Standard Deviation, Microarray, Gene Expression, Western Blot, Boyden Chamber Assay, Control, Two Tailed Test

    Effect of cyclin d1 and Id1 on EMT markers . MDA-MB-231 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in EMT-related gene expression by microarray analysis. Additionally, MDA-MB-231 and ZR75-1 gene expression was examined by qPCR assay. Plots are mean values from at least three independent experiments Error bars represent standard deviation. (A) Microarray analysis of SNAI1 , SNAI2 , CDH11 , TWIST1 and VIM gene expression. (B-D) CCND1, ID1 and SNAI2 in MDA-MB-231 cells. (E, F) qPCR analysis of CCND1 and SNAI2 in ZR75-1 cells. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.
    Figure Legend Snippet: Effect of cyclin d1 and Id1 on EMT markers . MDA-MB-231 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in EMT-related gene expression by microarray analysis. Additionally, MDA-MB-231 and ZR75-1 gene expression was examined by qPCR assay. Plots are mean values from at least three independent experiments Error bars represent standard deviation. (A) Microarray analysis of SNAI1 , SNAI2 , CDH11 , TWIST1 and VIM gene expression. (B-D) CCND1, ID1 and SNAI2 in MDA-MB-231 cells. (E, F) qPCR analysis of CCND1 and SNAI2 in ZR75-1 cells. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

    Techniques Used: Transfection, Plasmid Preparation, Gene Expression, Microarray, Standard Deviation, Control, Two Tailed Test

    Distribution of CCND1 and ID1 gene expression according to clinico- pathological parameters in breast cancer patients
    Figure Legend Snippet: Distribution of CCND1 and ID1 gene expression according to clinico- pathological parameters in breast cancer patients

    Techniques Used: Gene Expression

    Correlation of CCND1 , ID1 , SNAI1 and SNAI2 expression to recurrence free survival . Expression of our genes of interest in relation to recurrence-free survival was examined in a breast cancer database containing 1,107 tumours from Sims et al. (2008). Gene expression intensity was quartiled as 1-low, 2- medium low, 3- medium high and 4- high, and assessed in all patients, ER-positive and ER-negative patients, respectively (A) CCND1 quartiles (B) ID1 quartiles (C) SNAI1 quartiles (D) SNAI2 quartiles. P-value is based on log-rank test.
    Figure Legend Snippet: Correlation of CCND1 , ID1 , SNAI1 and SNAI2 expression to recurrence free survival . Expression of our genes of interest in relation to recurrence-free survival was examined in a breast cancer database containing 1,107 tumours from Sims et al. (2008). Gene expression intensity was quartiled as 1-low, 2- medium low, 3- medium high and 4- high, and assessed in all patients, ER-positive and ER-negative patients, respectively (A) CCND1 quartiles (B) ID1 quartiles (C) SNAI1 quartiles (D) SNAI2 quartiles. P-value is based on log-rank test.

    Techniques Used: Expressing, Gene Expression

    EMT-related gene expression intensity and recurrence free survival in CCND1 / ID1 high and low tumours . A breast cancer database was employed to examine (A) Mean-centered average expression of EMT-related genes of interest in CCND1 / ID1 subgroups, and (B, C) Recurrence-free survival of ER-positive and negative patients in CCND1 / ID1 subgroups. P-value is based on log-rank test.
    Figure Legend Snippet: EMT-related gene expression intensity and recurrence free survival in CCND1 / ID1 high and low tumours . A breast cancer database was employed to examine (A) Mean-centered average expression of EMT-related genes of interest in CCND1 / ID1 subgroups, and (B, C) Recurrence-free survival of ER-positive and negative patients in CCND1 / ID1 subgroups. P-value is based on log-rank test.

    Techniques Used: Gene Expression, Expressing

    Gene expression of Cyclin d1/Id1 and EMT markers in breast cancer cell lines and claudin-low tumours . Expression of EMT and related genes from the Neve et al cell line (A-C) and Herschkowitz et al. claudin-low (D-F) studies. (A and D) Heatmaps showing relative expression of genes of interest, Red = high, Green = low. (B and E) Scatterplots showing the relationship between breast cancer subgroups and CCND1 / ID1 expression (C and F) Proportion of CCND1- low/ ID1 -high cell lines and tumours in breast cancer subgroups. ***P ≥ 0.001 , Chi 2 test.
    Figure Legend Snippet: Gene expression of Cyclin d1/Id1 and EMT markers in breast cancer cell lines and claudin-low tumours . Expression of EMT and related genes from the Neve et al cell line (A-C) and Herschkowitz et al. claudin-low (D-F) studies. (A and D) Heatmaps showing relative expression of genes of interest, Red = high, Green = low. (B and E) Scatterplots showing the relationship between breast cancer subgroups and CCND1 / ID1 expression (C and F) Proportion of CCND1- low/ ID1 -high cell lines and tumours in breast cancer subgroups. ***P ≥ 0.001 , Chi 2 test.

    Techniques Used: Gene Expression, Expressing

    Related Articles

    Positive Control:

    Article Title: Cyclin D1, Id1 and EMT in breast cancer
    Article Snippet: ChIP assay was carried out using the MAGnifyTM Chromatin Immunoprecipitation System (Invitrogen Life Technologies, Carlsbad, CA). .. 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK). ..



    Similar Products

    simplechiptm human id1 promoter primers  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc simplechiptm human id1 promoter primers
    Effect of cyclin D1 and <t>Id1</t> on breast cancer cell protein expression and migration . Actively cycling MDA-MB-231 and ZR75-1 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in gene or protein expression, and migration. Blots are representative, and plots are mean values from at least three independent experiments. Error bars represent standard deviation. MDA-MB-231 cells: (A) Microarray analysis. Left panel: CCND1 gene expression, right panel: ID1 gene expression (B) Western blot for cyclin d1, Id1 and Actin protein, (C) Cell migration as measured by Boyden chamber assay, dots indicate total number of migrated cells. (D) ChIP assay for Id1 promoter region following cyclin D1 pull down. ZR75-1: (E) Western blot for cyclin d1 and Actin protein (F) Cell migration- Boyden chamber assay. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.
    Simplechiptm Human Id1 Promoter Primers, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/simplechiptm+human+id1+promoter+primers/SimpleChIP+Human+ID1+Promoter+Primers/pmc03192789-81-22-27
    Average 93 stars, based on 1 article reviews
    simplechiptm human id1 promoter primers - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Effect of cyclin D1 and Id1 on breast cancer cell protein expression and migration . Actively cycling MDA-MB-231 and ZR75-1 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in gene or protein expression, and migration. Blots are representative, and plots are mean values from at least three independent experiments. Error bars represent standard deviation. MDA-MB-231 cells: (A) Microarray analysis. Left panel: CCND1 gene expression, right panel: ID1 gene expression (B) Western blot for cyclin d1, Id1 and Actin protein, (C) Cell migration as measured by Boyden chamber assay, dots indicate total number of migrated cells. (D) ChIP assay for Id1 promoter region following cyclin D1 pull down. ZR75-1: (E) Western blot for cyclin d1 and Actin protein (F) Cell migration- Boyden chamber assay. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

    Journal: BMC Cancer

    Article Title: Cyclin D1, Id1 and EMT in breast cancer

    doi: 10.1186/1471-2407-11-417

    Figure Lengend Snippet: Effect of cyclin D1 and Id1 on breast cancer cell protein expression and migration . Actively cycling MDA-MB-231 and ZR75-1 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in gene or protein expression, and migration. Blots are representative, and plots are mean values from at least three independent experiments. Error bars represent standard deviation. MDA-MB-231 cells: (A) Microarray analysis. Left panel: CCND1 gene expression, right panel: ID1 gene expression (B) Western blot for cyclin d1, Id1 and Actin protein, (C) Cell migration as measured by Boyden chamber assay, dots indicate total number of migrated cells. (D) ChIP assay for Id1 promoter region following cyclin D1 pull down. ZR75-1: (E) Western blot for cyclin d1 and Actin protein (F) Cell migration- Boyden chamber assay. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

    Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

    Techniques: Expressing, Migration, Transfection, Plasmid Preparation, Standard Deviation, Microarray, Gene Expression, Western Blot, Boyden Chamber Assay, Control, Two Tailed Test

    Effect of cyclin d1 and Id1 on EMT markers . MDA-MB-231 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in EMT-related gene expression by microarray analysis. Additionally, MDA-MB-231 and ZR75-1 gene expression was examined by qPCR assay. Plots are mean values from at least three independent experiments Error bars represent standard deviation. (A) Microarray analysis of SNAI1 , SNAI2 , CDH11 , TWIST1 and VIM gene expression. (B-D) CCND1, ID1 and SNAI2 in MDA-MB-231 cells. (E, F) qPCR analysis of CCND1 and SNAI2 in ZR75-1 cells. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

    Journal: BMC Cancer

    Article Title: Cyclin D1, Id1 and EMT in breast cancer

    doi: 10.1186/1471-2407-11-417

    Figure Lengend Snippet: Effect of cyclin d1 and Id1 on EMT markers . MDA-MB-231 cells were monitored 20 h post-transfection with the indicated siRNA (cyclin D1/CDK4/6/Id1) or vector (Id1) for changes in EMT-related gene expression by microarray analysis. Additionally, MDA-MB-231 and ZR75-1 gene expression was examined by qPCR assay. Plots are mean values from at least three independent experiments Error bars represent standard deviation. (A) Microarray analysis of SNAI1 , SNAI2 , CDH11 , TWIST1 and VIM gene expression. (B-D) CCND1, ID1 and SNAI2 in MDA-MB-231 cells. (E, F) qPCR analysis of CCND1 and SNAI2 in ZR75-1 cells. ***P ≥ 0.001, **P ≥ 0.01, *P ≥ 0.05 vs. control, two-tailed student's t-test.

    Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

    Techniques: Transfection, Plasmid Preparation, Gene Expression, Microarray, Standard Deviation, Control, Two Tailed Test

    Distribution of CCND1 and ID1 gene expression according to clinico- pathological parameters in breast cancer patients

    Journal: BMC Cancer

    Article Title: Cyclin D1, Id1 and EMT in breast cancer

    doi: 10.1186/1471-2407-11-417

    Figure Lengend Snippet: Distribution of CCND1 and ID1 gene expression according to clinico- pathological parameters in breast cancer patients

    Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

    Techniques: Gene Expression

    Correlation of CCND1 , ID1 , SNAI1 and SNAI2 expression to recurrence free survival . Expression of our genes of interest in relation to recurrence-free survival was examined in a breast cancer database containing 1,107 tumours from Sims et al. (2008). Gene expression intensity was quartiled as 1-low, 2- medium low, 3- medium high and 4- high, and assessed in all patients, ER-positive and ER-negative patients, respectively (A) CCND1 quartiles (B) ID1 quartiles (C) SNAI1 quartiles (D) SNAI2 quartiles. P-value is based on log-rank test.

    Journal: BMC Cancer

    Article Title: Cyclin D1, Id1 and EMT in breast cancer

    doi: 10.1186/1471-2407-11-417

    Figure Lengend Snippet: Correlation of CCND1 , ID1 , SNAI1 and SNAI2 expression to recurrence free survival . Expression of our genes of interest in relation to recurrence-free survival was examined in a breast cancer database containing 1,107 tumours from Sims et al. (2008). Gene expression intensity was quartiled as 1-low, 2- medium low, 3- medium high and 4- high, and assessed in all patients, ER-positive and ER-negative patients, respectively (A) CCND1 quartiles (B) ID1 quartiles (C) SNAI1 quartiles (D) SNAI2 quartiles. P-value is based on log-rank test.

    Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

    Techniques: Expressing, Gene Expression

    EMT-related gene expression intensity and recurrence free survival in CCND1 / ID1 high and low tumours . A breast cancer database was employed to examine (A) Mean-centered average expression of EMT-related genes of interest in CCND1 / ID1 subgroups, and (B, C) Recurrence-free survival of ER-positive and negative patients in CCND1 / ID1 subgroups. P-value is based on log-rank test.

    Journal: BMC Cancer

    Article Title: Cyclin D1, Id1 and EMT in breast cancer

    doi: 10.1186/1471-2407-11-417

    Figure Lengend Snippet: EMT-related gene expression intensity and recurrence free survival in CCND1 / ID1 high and low tumours . A breast cancer database was employed to examine (A) Mean-centered average expression of EMT-related genes of interest in CCND1 / ID1 subgroups, and (B, C) Recurrence-free survival of ER-positive and negative patients in CCND1 / ID1 subgroups. P-value is based on log-rank test.

    Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

    Techniques: Gene Expression, Expressing

    Gene expression of Cyclin d1/Id1 and EMT markers in breast cancer cell lines and claudin-low tumours . Expression of EMT and related genes from the Neve et al cell line (A-C) and Herschkowitz et al. claudin-low (D-F) studies. (A and D) Heatmaps showing relative expression of genes of interest, Red = high, Green = low. (B and E) Scatterplots showing the relationship between breast cancer subgroups and CCND1 / ID1 expression (C and F) Proportion of CCND1- low/ ID1 -high cell lines and tumours in breast cancer subgroups. ***P ≥ 0.001 , Chi 2 test.

    Journal: BMC Cancer

    Article Title: Cyclin D1, Id1 and EMT in breast cancer

    doi: 10.1186/1471-2407-11-417

    Figure Lengend Snippet: Gene expression of Cyclin d1/Id1 and EMT markers in breast cancer cell lines and claudin-low tumours . Expression of EMT and related genes from the Neve et al cell line (A-C) and Herschkowitz et al. claudin-low (D-F) studies. (A and D) Heatmaps showing relative expression of genes of interest, Red = high, Green = low. (B and E) Scatterplots showing the relationship between breast cancer subgroups and CCND1 / ID1 expression (C and F) Proportion of CCND1- low/ ID1 -high cell lines and tumours in breast cancer subgroups. ***P ≥ 0.001 , Chi 2 test.

    Article Snippet: 3 μg of anti-cyclin d1 antibody (DCS-6, DAKO, Denmark) was used to pull down cyclin D1, with subsequent detection of Id1 using SimpleChIPTM Human Id1 Promoter Primers (Cell Signalling Technology, Danvers, MA) and Mrg1 as positive control (Eurofins Laboratories Ltd., Manchester, UK).

    Techniques: Gene Expression, Expressing